Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Olaratumab |
| Synonyms | |
| Therapy Description |
Lartruvo (olaratumab) is a monoclonal antibody that targets PDGFR-alpha and prevents ligand binding, potentially leading to decreased angiogenesis and reduced proliferation of tumor cells (PMID: 27291997). Lartruvo (olaratumab) in combination with doxorubicin is FDA approved for patients with soft tissue sarcoma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Olaratumab | Lartruvo | IMC-3G3 | PDGFRA Antibody 2 | Lartruvo (olaratumab) is a monoclonal antibody that targets PDGFR-alpha and prevents ligand binding, potentially leading to decreased angiogenesis and reduced proliferation of tumor cells (PMID: 27291997). Lartruvo (olaratumab) in combination with doxorubicin is FDA approved for patients with soft tissue sarcoma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02451943 | Phase III | Olaratumab Doxorubicin | A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma | Completed | USA | SWE | POL | NLD | ITA | ISR | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 5 |
| NCT03056599 | Phase I | Pembrolizumab Avelumab Interferon gamma Olaratumab Trabectedin Nivolumab Gemcitabine Interferon alpha-2b Doxorubicin Atezolizumab Eribulin Ipilimumab Durvalumab Aldesleukin Bortezomib Docetaxel | Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma | Completed | USA | 0 |
| NCT02677116 | Phase I | Doxorubicin Ifosfamide Irinotecan + Vincristine Sulfate Olaratumab | A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer | Completed | USA | 1 |
| NCT02659020 | Phase Ib/II | Olaratumab Docetaxel + Gemcitabine | A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma | Completed | USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | AUS | 0 |
| NCT03994627 | Expanded access | Olaratumab | Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma | Available | USA | ITA | HUN | GBR | ESP | CAN | BRA | AUT | 3 |
CKB BOOST